Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2963-2970

  Gabrilovich, Dmitry I ^a,b   Ishida, Tadao ^a   Nadaf, Sorena ^a   Ohm, Joyce E ^a   Carbone, David P ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; DENDRITIC CELL; FEMALE; GENE THERAPY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SARCOMA; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; DENDRITIC CELLS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNIZATION; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032741283     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
2. Ioannides, C., and Whiteside, T. T cell recognition of human tumors: implication for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol., 66: 91-106, 1993.
3. Kavanaugh, D. Y., and Carbone, D. P. Immunologic dysfunction in cancer. Hematol. Oncol. Clin. N. Am., 10: 927-951, 1996.
4. Gabrilovich, D., Ciernik, F., and Carbone, D. P. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol., 170: 101-110, 1996.
5. Tas, M., Simons, P., Balm, F., and Drexhage, H. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother., 36: 108-114, 1993.
6. Nestle, F. O., Burg, G., Fah, J., Wrone-Smith, T., and Nickoloff, B. J. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol., 150: 641-651, 1997.
7. Chaux, P., Moutet, M., Faivre, J., Martin, F., and Martin, M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab. Investig., 74: 975-983, 1996.
8. Chaux, P., Favre, N., Martin, M., and Martin, F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer, 72: 619-624, 1997.
9. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., and Carbone, D. P. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res., 3: 483-490, 1997.
10. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A., and Carbone, D. P. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol., 170: 111-120, 1996.
11. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., and Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103, 1996.
12. Steinbrink, K., Woffl, M., Jonuleit, H., Knop, J., and Enk, A. H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol., 159: 4772-4780, 1997.
13. Menetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., and Blay, J. Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage-colony-stimulating factor. Blood, 92: 4778-4791, 1998.
14. Jasani, B., Navabi, H., Adams, M., Evans, A., and Mason, M. Serum dependent down-regulation of CD1a expression and specific CTL priming activity in human dendritic cells. Proc. Am. Assoc. Cancer Res., 30: 611, 1998.
15. Ishida, T., Oyama, T., Carbone, D., and Gabrilovich, D. I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. J. Immunol., 161: 4842-4851, 1998.
16. Ferrara, N., and Smyth, D. T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
17. Gabrilovich, D. I., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., and Carbone, D. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92: 4150-4166, 1998.
18. + cytotoxic T-cells. Cancer Res., 53: 3257-3261, 1993.
19. Gabrilovich, D. I., Cunningham, H. T., and Carbone, D. P. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J. Immunother., 19: 414-418, 1997.
20. Noguchi, Y., Chen, Y., and Old, L. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA, 91: 3171-3175, 1994.
21. Noguchi, Y., Richards, E. C., Chen Y-T., and Old, L. Influence of interleukin 12 on p53 peptide vaccination against established MethA sarcoma. Proc. Natl. Acad. Sci. USA, 92: 2219-2223, 1995.
22. Takahashi, H., Cohen, J., Hosmalin, A., Cease, K. B., Houghten, R., Cornette, J., DeLisi, C., Moss, B., Germain, R. N., and Berzofsky, J. A. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA, 85: 3105-3109, 1988.
23. Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., Maruno, T., Shirai, S., and Nose, T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res., 56: 2185-2190, 1996.
24. Kondo, S., Asano, M., Matsuo, K., Ohmori, I., and Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta, 1221: 211-214, 1994.
25. Dirix, L. Y., Vermeulen, P. B., Pawinski, A., Prove, A., Benoy, I., De Pooter C., Martin, M., and Van Oosterom, A. T. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer, 76: 238-243, 1997.
26. Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., and Ferrara, N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma microtumors in vivo. Prostate, 35: 1-10, 1998.
27. Borgstrom, P., Hillan, K. J., Sriramarao, P., and Ferrara, N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res., 56: 4032-4039, 1996.
28. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
29. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D., and Gabrilovich, D. I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hematopoietic progenitor cells. J. Immunol., 160: 1224-1232, 1998.
30. Kim, K. J., Li, B., Winer, J., Armanini, M., Gilett, N., Fillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
31. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Investig., 95: 1789-1797, 1995.
32. Grabbe, S., Gallo, R. L., Lindgren, A., and Granstein, R. D. Deficient antigen presentation by Langerhans cells from athymic (nu/nu) mice: restoration with thymic transplantation or administration of cytokines. J. Immunol., 151: 3430-3439, 1993.